Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, seasoning as a public company and other criteria. The index is re-ranked annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.
For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
For KemPharm, Inc.: Gordon K. ”Rusty” Johnson 321-939-3416 [email protected] Media / Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected]
